№ US20260000632A1発明
審査中STRUCTURALLY MODIFIED FATTY ACIDS FOR IMPROVING GLYCEMIC CONTROL AND TREATING INFLAMMATORY BOWEL DISEASE
STRUCTURALLY MODIFIED FATTY ACIDS FOR IMPROVING GLYCEMIC CONTROL AND TREATING INFLAMMATORY BOWEL DISEASE
The present disclosure provides a compound for use as an activator of enteroendocrine GLP-1 production, improving glycemic control, and treating inflammatory bowel disease, wherein the compound is a structurally modified unsaturated fatty acid with an α-substituent, either alone or in combination with one or more additional therapeutic agents.
❖Northsea Therapeutics B.V.; BASF ASDavid Alan FRASER; Tore SKJAERET; Detlef SCHUPPAN§ 2/19 請求項A61K 31/202, A61K 9/, A61K 45/6 +212